# REMoDL-A (NCT04546620)

> Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

No report yet. It can be ordered.

- Drugs tested: acalabrutinib
- Indication: previously untreated diffuse large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04546620
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University Hospital Southampton NHS Foundation Trust
- Conditions: Diffuse Large B Cell Lymphoma
- Interventions: R-CHOP; R-CHOP + acalabrutinib
- Enrollment: 453
- Primary outcome: To establish if combining acalabrutinib with R-CHOP improves efficacy, compared to RCHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.

## Indexed commentary on REMoDL-A so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=remodl-a-nct04546620